Although our in vivo results are promising, a limitation noted in this study was the use on only one cell line for in vivo testing, therefore, additional in vivo studies using cell lines with variable NAMPT and NAPRT levels are needed to fully understand the impact of NAMPT targeting in NB. The gene discussed is NAMPT; the disease is neuroblastoma.